The study of Avastin (bevacizumab) to reverse acquired estrogen independence in metastatic breast cancer patients previously responsive to hormonal therapy: a phase II trial

Trial Profile

The study of Avastin (bevacizumab) to reverse acquired estrogen independence in metastatic breast cancer patients previously responsive to hormonal therapy: a phase II trial

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 26 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Dec 2010 Planned end date changed from 1 Dec 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top